Binimetinib

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H15BrF2N4O3
Molecular Weight	441.227
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=CC=C(Br)C=C3F)=C2F

InChI

InChIKey=ACWZRVQXLIRSDF-UHFFFAOYSA-N

InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

HIDE SMILES / InChI

Molecular Formula	C17H15BrF2N4O3
Molecular Weight	441.227
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.arraybiopharma.com/product-pipeline/binimetinib/
Curator's Comment: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C84865 | https://www.ncbi.nlm.nih.gov/pubmed/23635776 | https://acr.confex.com/acr/2006/webprogram/Paper5558.html

Binimetinib (MEK162) is an oral small-molecule with potential antineoplastic activity. It is a selective mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, a key protein kinase in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Inappropriate activation of this pathway has been shown to occur in many cancers, in particular through mutations in BRAF, KRAS and NRAS. MEK162 at 6 mg/kg, BID combined with BEZ235 (dual PI3K/mTOR inhibitor) resulted in a significant reduction of tumor growth in immunodeficient mice injected with MCF7 cells. There are three ongoing Phase 3 trials with binimetinib in advanced cancer patients: NEMO (NRAS-mutant melanoma), COLUMBUS (encorafenib in combination with binimetinib in BRAF-mutant melanoma) and BEACON CRC (encorafenib, binimetinib and cetuximab in BRAF-mutant colorectal cancer).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mitogen-activated protein kinase kinase kinase 1 1 Target ID: CHEMBL3956 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27149444 \| https://www.ncbi.nlm.nih.gov/pubmed/25937299	Inhibitor 8504		12.0 nM [IC50]
Dual specificity mitogen-activated protein kinase kinase 2 10 Target ID: CHEMBL2964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27149444 \| https://www.ncbi.nlm.nih.gov/pubmed/25937299	Inhibitor 8504		12.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Metastatic or unresectable cutaneous melanoma 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf	Primary		Approved 8583	MEKTOVI Approved Use is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test Launch Date 2018
BRAF V600E-mutant metastatic colorectal cancer 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02928224	Primary		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
545 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28152546	60 mg 2 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BINIMETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
241 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28152546	45 mg 2 times / day multiple, oral dose: 45 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BINIMETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1710 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28152546	60 mg 2 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BINIMETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
964 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28152546	45 mg 2 times / day multiple, oral dose: 45 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BINIMETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/	unhealthy, 58 years (range: 30–86 years) Health Status: unhealthy Age Group: 58 years (range: 30–86 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/	DLT: Chorioretinopathy, Dermatitis acneiform... Disc. AE: Macular oedema, Nausea... Other AEs: Retinal deposits, Retinopathy... Dose limiting toxicities: Chorioretinopathy (grade 3, 25%) Dermatitis acneiform (grade 3, 25%) AEs leading to discontinuation/dose reduction: Macular oedema (grade 3-4, 25%) Nausea (grade 1-2, 25%) Vomiting (grade 1-2, 50%) Fatigue (grade 1-2, 25%) Other AEs: Retinal deposits (grade 3-4, 25%) Retinopathy (grade 3-4, 25%) Papilloedema (grade 3-4, 25%) Retinal detachment (grade 3-4, 25%) Retinal disorder (grade 3-4, 25%) Acne (grade 3-4, 25%) Skin exfoliation (grade 3-4, 25%) Diarrhoea (grade 1-2, 25%) Peripheral oedema (grade 1-2, 50%) Abdominal pain (grade 1-2, 25%) Anorexia (grade 1-2, 25%) Dyspnoea (grade 1-2, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/
60 mg 2 times / day steady, oral MTD Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/	unhealthy, 58 years (range: 30–86 years) Health Status: unhealthy Age Group: 58 years (range: 30–86 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/	Disc. AE: Dermatitis acneiform, Acne... Other AEs: Diarrhoea, Peripheral oedema... AEs leading to discontinuation/dose reduction: Dermatitis acneiform (grade 1-2, 85%) Acne (grade 1-2, 85%) Skin exfoliation (grade 1-2, 85%) Dermatitis acneiform (grade 3-4, 2%) Acne (grade 3-4, 2%) Skin exfoliation (grade 3-4, 2%) Nausea (grade 1-2, 51%) Vomiting (grade 1-2, 49%) Fatigue (grade 1-2, 39%) Fatigue (grade 3-4, 2%) Other AEs: Diarrhoea (grade 1-2, 61%) Peripheral oedema (grade 1-2, 51%) Anaemia (grade 1-2, 12%) Anaemia (grade 3-4, 24%) Abdominal pain (grade 1-2, 17%) Abdominal pain (grade 3-4, 7%) Anorexia (grade 1-2, 20%) Constipation (grade 1-2, 20%) Constipation (grade 3-4, 5%) Dyspnoea (grade 1-2, 15%) Dyspnoea (grade 3-4, 2%) Pyrexia (grade 1-2, 17%) Pyrexia (grade 3-4, 2%) Dizziness (grade 1-2, 22%) Pulmonary embolism (grade 4, 1 patient) Generalised oedema (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/
60 mg 2 times / day steady, oral MTD Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/28152546	unhealthy, 58 years (range: 30–86 years) Health Status: unhealthy Age Group: 58 years (range: 30–86 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/28152546	Disc. AE: Retinal deposits, Retinopathy... Other AEs: Papilloedema, Retinal disorder... AEs leading to discontinuation/dose reduction: Retinal deposits (grade 1-2, 27%) Retinopathy (grade 1-2, 27%) Chorioretinopathy (grade 1-2, 27%) Macular oedema (grade 1-2, 27%) Retinal detachment (grade 1-2, 27%) Other AEs: Papilloedema (grade 1-2, 27%) Retinal disorder (grade 1-2, 27%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/28152546
45 mg 2 times / day steady, oral RP2D Dose: 45 mg, 2 times / day Route: oral Route: steady Dose: 45 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/	unhealthy, 58 years (range: 30–86 years) Health Status: unhealthy Age Group: 58 years (range: 30–86 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/	Disc. AE: Chorioretinopathy, Macular oedema... Other AEs: Retinal deposits, Retinopathy... AEs leading to discontinuation/dose reduction: Chorioretinopathy (grade 1-2, 11%) Macular oedema (grade 1-2, 11%) Retinal detachment (grade 1-2, 11%) Dermatitis acneiform (grade 1-2, 75%) Acne (grade 1-2, 75%) Skin exfoliation (grade 1-2, 75%) Dermatitis acneiform (grade 3-4, 2%) Acne (grade 3-4, 2%) Skin exfoliation (grade 3-4, 2%) Nausea (grade 1-2, 61%) Vomiting (grade 1-2, 52%) Diarrhoea (grade 1-2, 39%) Fatigue (grade 1-2, 41%) Fatigue (grade 3-4, 5%) Other AEs: Retinal deposits (grade 1-2, 11%) Retinopathy (grade 1-2, 11%) Papilloedema (grade 1-2, 11%) Retinal disorder (grade 1-2, 11%) Peripheral oedema (grade 1-2, 45%) Anaemia (grade 1-2, 11%) Anaemia (grade 3-4, 7%) Abdominal pain (grade 1-2, 16%) Abdominal pain (grade 3-4, 2%) Anorexia (grade 1-2, 18%) Constipation (grade 1-2, 14%) Dyspnoea (grade 1-2, 11%) Dyspnoea (grade 3-4, 5%) Pyrexia (grade 1-2, 16%) Dizziness (grade 1-2, 11%) Sources: https://pubmed.ncbi.nlm.nih.gov/28152546/
45 mg 2 times / day steady, oral Recommended Dose: 45 mg, 2 times / day Route: oral Route: steady Dose: 45 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf	Disc. AE: Left ventricular dysfunction, Serous retinopathy... Other AEs: Fatigue, Pyrexia... AEs leading to discontinuation/dose reduction: Left ventricular dysfunction (6%) Serous retinopathy (5%) Left ventricular dysfunction (3%) Serous retinopathy (3%) Colitis (2%) Hemorrhage (2%) Headache (1%) Other AEs: Fatigue (grade 3-4, 3%) Pyrexia (grade 3-4, 4%) Peripheral edema (grade 3-4, 1%) Fatigue (all grades, 43%) Pyrexia (all grades, 18%) Peripheral edema (all grades, 13%) Nausea (grade 3-4, 2%) Diarrhea (grade 3-4, 3%) Vomiting (grade 3-4, 2%) Abdominal pain (grade 3-4, 4%) Nausea (all grades, 41%) Diarrhea (all grades, 36%) Vomiting (all grades, 30%) Abdominal pain (all grades, 28%) Constipation (all grades, 22%) Rash (grade 3-4, 1%) Rash (all grades, 22%) Dizziness (grade 3-4, 3%) Dizziness (all grades, 15%) Visual impairment (all grades, 20%) Serous retinopathy (grade 3-4, 3%) Serous retinopathy (all grades, 20%) Hemorrhage (grade 3-4, 3%) Hemorrhage (all grades, 19%) Hypertension (grade 3-4, 6%) Hypertension (all grades, 11%) Anemia (grade 3-4, 3.6%) Anemia (all grades, 36%) Leukopenia (all grades, 13%) Lymphopenia (grade 3-4, 2.1%) Lymphopenia (all grades, 13%) Neutropenia (grade 3-4, 3.1%) Neutropenia (all grades, 13%) Creatinine increased (grade 3-4, 3.6%) Creatinine increased (all grades, 93%) Creatine phosphokinase increased (grade 3-4, 5%) Creatine phosphokinase increased (all grades, 58%) Gamma-glutamyltransferase increased (grade 3-4, 11%) Gamma-glutamyltransferase increased (all grades, 45%) ALT increased (grade 3-4, 6%) ALT increased (all grades, 29%) AST increased (grade 3-4, 2.6%) AST increased (all grades, 27%) Alkaline phosphatase increased (grade 3-4, 0.5%) Alkaline phosphatase increased (all grades, 21%) Hyponatremia (grade 3-4, 3.6%) Hyponatremia (all grades, 18%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inducer 440 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779 UGT1A 4 CYP1A2 2153 CYP2A6 879 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 CYP3A4/5 296 CYP2B6 926	CYP1A1 389 CYP1A2 1197 CYP2C19 1119 P-gp 2052 BCRP 697 UGT 219 UGT1A1 479 OCT1 393 OATP1B1 503 OATP1B3 435 OATP2B1 122

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2A6 911	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=61 Page: -	weak [IC50 18.1 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	weak [IC50 50 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	weak [IC50 50 uM]
UGT1A 6	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=61 Page: -	weak [IC50 >25 uM]
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=61 Page: -	weak	unlikely Comment: It is not expected for binimetinib to have a clinically relevant induction of CYP2C9, as the plasma concentrations observed in patients is well below the concentration required for minimal induction of CYP2C9 based on in vitro study Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=61 Page: -
CYP2B6 1160	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf#page=30 Page: -	yes [IC50 6 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 389	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=41 Page: -	major
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=41 Page: -	major
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=41 Page: -	major
UGT1A1 479	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=54 Page: -	major	no (co-administration study) Comment: atazanavir did not alter the exposure of BINIMETINIB Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=54 Page: -
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=41 Page: -	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=59 Page: -	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=59 Page: -	no
OATP2B1 122	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=59 Page: -	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=59 Page: -	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=41 Page: -	no	no (co-administration study) Comment: did not alter the exposure of midazolam Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=41 Page: -
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=59 Page: -	yes
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=59 Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf#page=33 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:145371	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:145371
ChemicalBook	CB82604200	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82604200
MolPort	MolPort-028-720-357	https://www.molport.com/shop/molecule-link/MolPort-028-720-357
ZINC	ZINC000038460704	http://zinc15.docking.org/substances/ZINC000038460704

PubMed

Title	Date	PubMed
MEK and the inhibitors: from bench to bedside.	2013 Apr 12	23587417
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.	2013 Jun	23635776
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.	2013 Mar	23414587
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.	2013 May-Jun	23608443
MEK1/2 inhibitors in the treatment of gynecologic malignancies.	2014 Apr	24434059
MEK targeting in N-RAS mutated metastatic melanoma.	2014 Mar 4	24588908
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.	2014 Sep 25	24141786

Patents

Sample Use Guides

In Vivo Use Guide

MEK162 administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.

Route of Administration: Oral

In Vitro Use Guide

MCF7 (mutant PIK3CA) breast cancer cells exhibiting sensitivity to PI3K inhibition were seeded in 12-well plates (2 × 10^4). After 24 hours, cells were treated with BEZ235, BKM120, GDC-0941, or MK2206 alone or in combination with MEK162. MEK162 (1 uM) combined with MK-2206 (2 mM) completely reversed the resistance of RSK-expressing MCF7 cells.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:07:47 GMT 2025` Edited by `admin` on `Wed Apr 02 07:07:47 GMT 2025`
Record UNII	181R97MR71
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Binimetinib

Official Name

English

MEKTOVI

Preferred Name

English

1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-

Systematic Name

English

binimetinib [INN]

Common Name

English

BINIMETINIB [USAN]

Common Name

English

BINIMETINIB [JAN]

Common Name

English

5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide

Systematic Name

English

MEK162

Code

English

Binimetinib [WHO-DD]

Common Name

English

ARRY-438162

Code

English

BINIMETINIB [MI]

Common Name

English

NVP-MEK162

Code

English

ARRY-162

Code

English

BINIMETINIB [ORANGE BOOK]

Common Name

English

6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

Systematic Name

English

MEK-162

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

440414